BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:Oligonucleotide R and D is accelerating\, driven by advances i
 n brain shuttle technologies\, RNA chemistry\, and growing clinical valid
 ation from leaders such as Alnylam Pharmaceuticals\, Stoke Therapeutics\,
  and Ionis Pharmaceuticals. At the same time\, major investments\, includ
 ing Novartis into Arrowhead Pharmaceuticals\, Biogen into City Therapeuti
 cs\, and Roche into Manifold Bio\, underscore CNS as a key frontier for t
 hese technologies\, unlocking previously undruggable targets.\n\nBuilding
  on last year's momentum\, the 6th Annual Oligonucleotides for CNS Summit
  will bring together 160+ experts across CNS biology\, oligo chemistry\, 
 RNA science\, and DMPK. Attendees will explore the latest innovations adv
 ancing nucleic acid therapies for neurodegenerative\, neuromuscular\, rar
 e\, epileptic\, and neurodevelopmental disorders.\n\nThis summit uniquely
  connects stakeholders at the intersection of oligonucleotides and CNS. J
 oin leaders from Eli Lilly\, Dyne Therapeutics\, Creyon Bio\, and more fo
 r three days of collaboration to accelerate RNA-targeted CNS therapies.\n
 \nDate and Time: Wednesday\, 19 August 2026 at 08:00 - Friday\, 21 August
  2026 at 17:00\n
DTEND:20260821T170000
DTSTAMP:20260507T074005Z
DTSTART:20260819T080000
LOCATION:The Colonnade Hotel\, 120 Huntington Avenue\, Boston\, Massachuse
 tts\, 02116\,
SEQUENCE:0
SUMMARY:Oligonucleotide R and D is accelerating\, driven by advances in br
 ain shuttle technologies\, RNA chemistry\, and growing clinical validatio
 n from lead...
UID:1d20e974-1075-4a1d-85e1-1923ba6d2b50
END:VEVENT
END:VCALENDAR